secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0001356576-25-000015
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus FY 2024 rev $661.8M; Qelbree +72%; ONAPGO approved; SPN-820 Phase 2b fails
--------------------------------------------------------------------------------

- Full year 2024 revenue $661.8M (+9% YoY); Qelbree net sales $241.3M (+72%) and GOCOVRI $130.8M (+9%).
- Full year 2024 operating earnings $81.7M vs loss of $(5.3)M in 2023; adjusted operating earnings $183.7M (+47%).
- ONAPGO (apomorphine) FDA approved for advanced Parkinson's; launch planned in Q2 2025.
- SPN-820 Phase 2b in treatment-resistant depression failed primary and secondary endpoints; program future under review.
- FY 2025 guidance: total revenues $600-630M; adjusted operating earnings $105-130M, down from $183.7M in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657625000015/0001356576-25-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657625000015/supn-20250225.htm
  HTML page:      https://secwatch.observer/filing/0001356576-25-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer